Teriflunomide + Evobrutinib
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsing Multiple Sclerosis
Conditions
Relapsing Multiple Sclerosis
Trial Timeline
Jun 12, 2020 → Mar 8, 2024
NCT ID
NCT04338022About Teriflunomide + Evobrutinib
Teriflunomide + Evobrutinib is a phase 3 stage product being developed by Merck for Relapsing Multiple Sclerosis. The current trial status is terminated. This product is registered under clinical trial identifier NCT04338022. Target conditions include Relapsing Multiple Sclerosis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04338061 | Phase 3 | Terminated |
| NCT04338022 | Phase 3 | Terminated |
Competing Products
20 competing products in Relapsing Multiple Sclerosis